Managing COPD to improve quality of life

Research output: Contribution to journalArticle

Abstract

The mortality rate for chronic obstructive pulmonary disease (COPD) has increased significantly in recent years. Although smoking cessation is still the most important intervention in COPD, a variety of pharmacologic therapies are available to help manage symptoms. Short-acting β2-agonists and/or ipratropium can be prescribed, with the use of additional therapies based on the severity of disease. Persons with moderate or severe COPD should regularly take 1 or more long-acting bronchodilators. The long-acting β2-agonists salmeterol and formoterol have been demonstrated to improve health-related quality of life. Newer therapies include the long-acting anticholinergic tiotropium and a salmeterol/fluticasone combination. These agents improve forced expiratory volume in 1 second and may reduce the rate of acute exacerbations. For patients with moderate to very severe COPD, participation in a pulmonary rehabilitation program can improve health status, quality of life, and exercise tolerance.

Original languageEnglish (US)
Pages (from-to)259-265
Number of pages7
JournalDrug Benefit Trends
Volume18
Issue number4
StatePublished - Apr 2006

Fingerprint

Chronic Obstructive Pulmonary Disease
Quality of Life
Ipratropium
Exercise Tolerance
Bronchodilator Agents
Forced Expiratory Volume
Cholinergic Antagonists
Smoking Cessation
Health Status
Therapeutics
Rehabilitation
Lung
Mortality

Keywords

  • β-Agonists
  • Anticholinergics
  • Chronic obstructive pulmonary disease
  • Smoking cessation

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Leadership and Management

Cite this

Managing COPD to improve quality of life. / Adams, Sandra G.

In: Drug Benefit Trends, Vol. 18, No. 4, 04.2006, p. 259-265.

Research output: Contribution to journalArticle

@article{77d9f911cc1f4913926b66cf40c498d7,
title = "Managing COPD to improve quality of life",
abstract = "The mortality rate for chronic obstructive pulmonary disease (COPD) has increased significantly in recent years. Although smoking cessation is still the most important intervention in COPD, a variety of pharmacologic therapies are available to help manage symptoms. Short-acting β2-agonists and/or ipratropium can be prescribed, with the use of additional therapies based on the severity of disease. Persons with moderate or severe COPD should regularly take 1 or more long-acting bronchodilators. The long-acting β2-agonists salmeterol and formoterol have been demonstrated to improve health-related quality of life. Newer therapies include the long-acting anticholinergic tiotropium and a salmeterol/fluticasone combination. These agents improve forced expiratory volume in 1 second and may reduce the rate of acute exacerbations. For patients with moderate to very severe COPD, participation in a pulmonary rehabilitation program can improve health status, quality of life, and exercise tolerance.",
keywords = "β-Agonists, Anticholinergics, Chronic obstructive pulmonary disease, Smoking cessation",
author = "Adams, {Sandra G}",
year = "2006",
month = "4",
language = "English (US)",
volume = "18",
pages = "259--265",
journal = "Drug Benefit Trends",
issn = "1080-5826",
publisher = "Cliggott Publishing Co.",
number = "4",

}

TY - JOUR

T1 - Managing COPD to improve quality of life

AU - Adams, Sandra G

PY - 2006/4

Y1 - 2006/4

N2 - The mortality rate for chronic obstructive pulmonary disease (COPD) has increased significantly in recent years. Although smoking cessation is still the most important intervention in COPD, a variety of pharmacologic therapies are available to help manage symptoms. Short-acting β2-agonists and/or ipratropium can be prescribed, with the use of additional therapies based on the severity of disease. Persons with moderate or severe COPD should regularly take 1 or more long-acting bronchodilators. The long-acting β2-agonists salmeterol and formoterol have been demonstrated to improve health-related quality of life. Newer therapies include the long-acting anticholinergic tiotropium and a salmeterol/fluticasone combination. These agents improve forced expiratory volume in 1 second and may reduce the rate of acute exacerbations. For patients with moderate to very severe COPD, participation in a pulmonary rehabilitation program can improve health status, quality of life, and exercise tolerance.

AB - The mortality rate for chronic obstructive pulmonary disease (COPD) has increased significantly in recent years. Although smoking cessation is still the most important intervention in COPD, a variety of pharmacologic therapies are available to help manage symptoms. Short-acting β2-agonists and/or ipratropium can be prescribed, with the use of additional therapies based on the severity of disease. Persons with moderate or severe COPD should regularly take 1 or more long-acting bronchodilators. The long-acting β2-agonists salmeterol and formoterol have been demonstrated to improve health-related quality of life. Newer therapies include the long-acting anticholinergic tiotropium and a salmeterol/fluticasone combination. These agents improve forced expiratory volume in 1 second and may reduce the rate of acute exacerbations. For patients with moderate to very severe COPD, participation in a pulmonary rehabilitation program can improve health status, quality of life, and exercise tolerance.

KW - β-Agonists

KW - Anticholinergics

KW - Chronic obstructive pulmonary disease

KW - Smoking cessation

UR - http://www.scopus.com/inward/record.url?scp=33750836889&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750836889&partnerID=8YFLogxK

M3 - Article

VL - 18

SP - 259

EP - 265

JO - Drug Benefit Trends

JF - Drug Benefit Trends

SN - 1080-5826

IS - 4

ER -